Try our Advanced Search for more refined results

Barba et al v. Shire US, Inc. et al

  1. October 16, 2015

    Adderall Antitrust Class Has Standing Questioned At Trial

    Questions of standing and the proposed methods for ascertaining qualified plaintiffs dominated oral arguments Friday on a renewed motion for class certification in an antitrust lawsuit accusing Shire US Inc. of paying off generic rivals to delay selling cheaper versions of Adderall.

  2. September 14, 2015

    Adderall Buyers Slam Drugmaker's Class Cert. Objections

    Consumers accusing Shire US Inc. of paying off generic rivals to delay selling cheaper versions of Adderall defended their bid for class certification in the antitrust suit Friday, arguing that under the drugmaker's logic it would be impossible to ever certify a consumer class action over pharmaceuticals.

  3. May 28, 2015

    No More Delays, Plaintiffs In Shire Pay-For-Delay Suit Told

    A federal judge shot down a request by a group of consumers to amend their complaint for a second time against Shire US Inc. in a pay-for-delay suit, noting Wednesday that the case has already been bogged down by delays.

  4. May 21, 2015

    Plaintiffs Gain Some Docs In Adderall Suit, May Get Others

    A Florida magistrate judge on Wednesday gave two sides fighting over the release of documents in a pay-for-delay putative class action a little of what each wanted, allowing drugmaker Shire US Inc. to keep some papers under wraps while ordering it to turn over others.

  5. April 20, 2015

    Plaintiffs Say Shire Withholding Docs In Pay-For-Delay Suit

    Plaintiffs in a pay-for-delay putative class action against Shire U.S. Inc. over attention deficit hyperactivity disorder drug Adderal XR asked a Florida federal judge to order the company to turn over certain documents, saying the materials aren't privileged as Shire claims.

  6. August 06, 2014

    Shire Seeks To Ax Adderall Antitrust Class Action In Fla.

    Shire U.S. Inc. urged a Florida federal judge on Tuesday to dismiss a putative class action accusing the company of scheming to delay generic versions of its attention-deficit-hyperactivity drug Adderall XR, arguing that their antitrust theory is "simply implausible."

  7. June 10, 2013

    Shire Says Patent Deals Didn't Block Generic Adderall

    Shire US Inc. pushed a Florida federal judge on Friday to chuck a putative class action alleging it kept unbranded versions of wildly popular attention deficit disorder drug Adderall XR off the market, arguing that its settlements of patent litigation didn't prevent generic competition.

  8. April 02, 2013

    Shire Faces Consumer Antitrust Claims Over Adderall

    Consumers in Pennsylvania and Florida hit Shire US Inc. with a pair of putative class actions this week accusing the pharmaceutical company of illegally stifling competition for Adderall XR, its blockbuster treatment for attention deficit hyperactivity disorder, with patent settlements and supply agreements with generic rivals.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!